On location

Polatuzumab Vedotin Combination Appears Effective in Relapsed/Refractory Follicular Lymphoma

Treatment with the CD79b-directed antibody drug conjugate polatuzumab vedotin, when combined with obinutuzumab and lenalidomide, was associated with high rates of complete response (CR)...

Test Issue

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.

On Location Redirect

eNewsletter Sign-up

Sign up for our enewsletter! Subscribe Unsubscribe First Name: Last Name:

Redirect Page


Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.